Roche/Genentech, OSI to pay $67M to Settle Drug Claims

Jun 08, 2016

Reuters

Genentech and OSI Pharmaceuticals will be paying $67 million to resolve claims they made misleading statements about the effectiveness of lung cancer drug Tarceva, according to the U.S. Justice Department, as reported in a Reuters article.

The claims alleged that between 2006 and 2011, the companies misrepresented the drug to doctors and healthcare providers to treat patients with non-small cell lung cancer, the department said.

As a part of the settlement, the federal government will get $62.6 million and state Medicaid programs will get $4.4 million.

Read the Reuters story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments